STOCK TITAN
  1. Home
  2. Sec-filings
  3. RGNX
  4. [Form 4] REGENXBIO Inc. Insider Trading Activity

REGENXBIO (NASDAQ: RGNX) grants RSUs and options to key officer

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

REGENXBIO Inc.'s Chief Strategy & Legal Officer, Patrick J. Christmas, reported new equity awards. On January 6, 2026, he received 73,749 shares of common stock through a time-based restricted stock unit award at a price of $0.00 per share. According to the award terms, 25% of these RSUs will vest on each of January 6, 2027, 2028, 2029 and 2030, as long as he continues providing service to the company.

He was also granted stock options for 39,650 shares of common stock with an exercise price of $14.18 per share. These options vest 25% after 12 months of continuous service, with the remaining balance vesting in equal monthly installments over the 36 months following January 6, 2027, subject to continued service, and expire on January 6, 2036. After these transactions, he directly holds 215,367 shares of common stock and 39,650 stock options.

Positive

  • None.

Negative

  • None.
Insider Christmas Patrick J.
Role Chief Strategy & Legal Officer
Type Security Shares Price Value
Grant/Award Stock Options (Right to buy) 39,650 $0.00 --
Grant/Award Common Stock 73,749 $0.00 --
Holdings After Transaction: Stock Options (Right to buy) — 39,650 shares (Direct); Common Stock — 215,367 shares (Direct)
Footnotes (1)
  1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer. 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Christmas Patrick J.
(Last) (First) (Middle)
C/O REGENXBIO INC.
9804 MEDICAL CENTER DRIVE
(Street)
ROCKVILLE MD 20850
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
REGENXBIO Inc. [ RGNX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Strategy & Legal Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/06/2026 A 73,749(1) A $0.00 215,367 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to buy) $14.18 01/06/2026 A 39,650 (2) 01/06/2036 Common Stock 39,650 $0.00 39,650 D
Explanation of Responses:
1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer.
2. 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer.
Remarks:
/s/ Patrick J. Christmas 01/08/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did RGNX officer Patrick J. Christmas report?

Patrick J. Christmas, Chief Strategy & Legal Officer of REGENXBIO Inc. (RGNX), reported receiving 73,749 RSU-based common shares at $0.00 per share and stock options on 39,650 shares with a $14.18 exercise price on January 6, 2026.

What is the vesting schedule for the 73,749 REGENXBIO RSUs granted to Patrick J. Christmas?

The 73,749 RSU shares vest in four equal installments. 25% of the shares vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030, provided he continues to serve the company.

How do the stock options granted to Patrick J. Christmas at REGENXBIO vest?

The 39,650 stock options with a $14.18 exercise price vest 25% after 12 months of continuous service. The remaining options vest in equal monthly installments over the 36 months following January 6, 2027, contingent on continued service, and expire on January 6, 2036.

How many REGENXBIO common shares does Patrick J. Christmas own after these grants?

Following these reported transactions, Patrick J. Christmas directly beneficially owns 215,367 shares of REGENXBIO common stock, as well as 39,650 stock options.

What role does Patrick J. Christmas hold at REGENXBIO (RGNX)?

Patrick J. Christmas is reported as an officer of REGENXBIO Inc., serving as the company’s Chief Strategy & Legal Officer, and he is not listed as a director or 10% owner in this filing.

Were the reported REGENXBIO transactions purchases or awards?

The transactions are reported with code "A", indicating awards or grants. The RSUs were granted at $0.00 per share, and the stock options were granted with a $14.18 exercise price.